Research from Boehringer Suggests Confocal HCS Better than Non-Confocal; Will Industry Follow? | GenomeWeb

As high-content screening techniques continue to gain a foothold in pharmaceutical discovery programs, a debate is emerging: Which type of system is more suitable for drug-discovery applications — laser-based confocal platforms or lamp-based, non-confocal CCD camera imagers?

Now, scientists from Boehringer Ingelheim have added to the growing body of scientific literature comparing confocal and non-confocal imaging for specific high-content screens by publishing a paper comparing the technologies in a commonly used fluorescence translocation assay.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.